- Home
- BNR vs CMMB Comparison
BNR vs CMMB Comparison
Compare BNR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- CMMB
- Stock Information
- Founded
- BNR 2014
- CMMB 2004
- Country
- BNR China
- CMMB Israel
- Employees
- BNR N/A
- CMMB N/A
- Industry
- BNR Medical Specialities
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- CMMB Health Care
- Exchange
- BNR Nasdaq
- CMMB Nasdaq
- Market Cap
- BNR 28.6M
- CMMB 27.0M
- IPO Year
- BNR 2020
- CMMB N/A
- Fundamental
- Price
- BNR $5.38
- CMMB $1.60
- Analyst Decision
- BNR
- CMMB Strong Buy
- Analyst Count
- BNR 0
- CMMB 3
- Target Price
- BNR N/A
- CMMB $7.33
- AVG Volume (30 Days)
- BNR 20.0K
- CMMB 119.1K
- Earning Date
- BNR 11-29-2024
- CMMB 11-14-2024
- Dividend Yield
- BNR N/A
- CMMB N/A
- EPS Growth
- BNR N/A
- CMMB N/A
- EPS
- BNR N/A
- CMMB N/A
- Revenue
- BNR $70,154,674.00
- CMMB N/A
- Revenue This Year
- BNR $52.90
- CMMB N/A
- Revenue Next Year
- BNR $48.35
- CMMB N/A
- P/E Ratio
- BNR N/A
- CMMB N/A
- Revenue Growth
- BNR N/A
- CMMB N/A
- 52 Week Low
- BNR $2.62
- CMMB $0.42
- 52 Week High
- BNR $9.99
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- BNR 80.41
- CMMB 52.53
- Support Level
- BNR $4.55
- CMMB $1.54
- Resistance Level
- BNR $3.89
- CMMB $1.73
- Average True Range (ATR)
- BNR 0.42
- CMMB 0.16
- MACD
- BNR 0.23
- CMMB 0.01
- Stochastic Oscillator
- BNR 99.26
- CMMB 45.45
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.